HealthDay operates under the strictest editorial standards. Our syndicated news content is completely independent of any financial interests, is based solely on industry-respected sources and the latest scientific research, and is carefully fact-checked by a team of industry experts to ensure accuracy.
- All articles are edited and checked for factual accuracy by our Editorial Team prior to being published.
- Unless otherwise noted, all articles focusing on new research are based on studies published in peer-reviewed journals or issued from independent and respected medical associations, academic groups and governmental organizations.
- Each article includes a link or reference to the original source.
- Any known potential conflicts of interest associated with a study or source are made clear to the reader.
Please see our Editorial and Fact-Checking Policy for more detail.Editorial and Fact-Checking Policy
HealthDay Editorial Commitment
HeathDay is committed to maintaining the highest possible levels of impartial editorial standards in the content that we present on our website. All of our articles are chosen independent of any financial interests. Editors and writers make all efforts to clarify any financial ties behind the studies on which we report.
WEDNESDAY, March 28 (HealthDay News) -- Following a conditioning regimen of lymphoid irradiation (TLI) and antithymocyte globulin (ATG), the majority of HLA-matched kidney and hematopoietic cell transplant recipients can be withdrawn from immunosuppressive drugs, according to a small study published online March 8 in the American Journal of Transplantation.
In a tolerance induction protocol, John D. Scandling, M.D., of the Stanford University School of Medicine in California, and colleagues studied 16 patients conditioned with TLI and ATG who were given kidney transplants and an injection of CD34+ hematopoietic progenitor cells and T cells from human leukocyte antigen-matched donors. Changes in chimerism, the balance of T-cell subsets, and responses to donor alloantigens were monitored.
The researchers found that 15 patients developed multilineage chimerism without graft-versus-host disease. In eight patients with chimerism for at least six months, antirejection medications were withdrawn for one to three years (mean, 28 months) without subsequent episodes of rejection. Drug withdrawal was occurring or had just occurred for four chimeric patients, and four patients experienced return of underlying disease or rejection episodes and consequently were not withdrawn. Compared with conventional naive CD4+ T cells, early high ratios of CD4+CD25+ regulatory T cells and natural killer T cells were seen in blood cells from all patients. Patients who were off drugs demonstrated specific unresponsiveness to alloantigens from donors.
"TLI and ATG promoted the development of persistent chimerism and tolerance in a cohort of patients given kidney transplants and hematopoietic donor cell infusions," the authors write.
This story may be outdated. We suggest some alternatives.
The content contained in this article is over two years old. As such our recommendation is that you reference the articles below for the latest updates on this topic. This article has been left on our site as a matter of historic record. Please contact us at firstname.lastname@example.org with any questions.
Updated on March 28, 2012